The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)

被引：0
|
作者：
Sumii, Toshihiko [1 ]
Fujimori, Nao [1 ]
Funakoshi, Akihiro [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Dept Gastroenterol, Fukuoka, Japan
来源：
PANCREAS | 2008年 / 37卷 / 01期
关键词：
D O I：
10.1097/01.mpa.0000325612.89290.b5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [21] Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)
    Ando, M., Sr.
    Yonemori, K.
    Yunokawa, M.
    Nakano, E.
    Kouno, T.
    Shimizu, C.
    Katsumata, N.
    Tamura, K.
    Arioka, H.
    Fujiwara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation
    Cunningham, D
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S1 - S8
  • [23] Final result of phase II study of irinotecan (CPT-11) plus oral S-1 for previously treated advanced NSCLC patients.
    Arai, Daisuke
    Soejima, Kenzo
    Naoki, Katsuhiko
    Ikemura, Shinnosuke
    Terai, Hideki
    Sato, Takashi
    Satomi, Ryousuke
    Nakayama, Souhei
    Yoda, Satoshi
    Ishioka, Kouta
    Ohgino, Keiko
    Miyata, Jun
    Kabata, Hiroki
    Miyazaki, Masaki
    Betsuyaku, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Yamazaki, K.
    Watanabe, M.
    Suzuki, N.
    Kusano, M.
    ONCOLOGY, 2007, 72 (1-2) : 58 - 63
  • [25] Phase I-II study of irinotecan (CPT-11) and nedaplatin (254S) in patients with advanced and recurrent cervical cancer
    Hashiguchi, Yasunori
    Tsuda, Hiroshi
    Nishimura, Sadako
    Nakata, Shinichi
    Miyama, Masato
    Yoshida, Chika
    Fukumasu, Hiroshi
    Nakamura, Tetsuo
    Sako, Hisao
    Kawamura, Naoki
    ANNALS OF ONCOLOGY, 2004, 15 : 135 - 135
  • [26] The current status of irinotecan (CPT-11) in the United States
    Rothenberg, ML
    CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 : 272 - 281
  • [27] Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Boige, V
    Taieb, J
    Hebbar, M
    Magherini, E
    Mignard, D
    Debaere, T
    Hannoun, L
    Tigaud, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 358S - 358S
  • [28] Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors
    Font, A
    Sanchez, JM
    Rosell, R
    Taron, M
    Martinez, E
    Guillot, M
    Manzano, JL
    Margeli, M
    Barnadas, A
    Abad, A
    LUNG CANCER, 2002, 37 (02) : 213 - 218
  • [29] CPT-11/CDDP in advanced cervical cancer. Phase II study of irinotecan combined with cisplatin as neoadjuvant chemotherapy in patients with locally advanced cervical squamous or adenosquamous cell carcinoma
    Sugiyama, T
    Fujiyoshi, K
    Imamura, K
    Ohta, S
    Nishida, T
    Kamura, T
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 467 - 471
  • [30] A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma
    Sanz-Altamira, PM
    O'Reilly, E
    Stuart, KE
    Raeburn, L
    Steger, C
    Kemeny, NE
    Saltz, LB
    ANNALS OF ONCOLOGY, 2001, 12 (04) : 501 - 504
12345